Key Drivers
- Very high gross
- Strong free cash
- R&D intensity
AIAI Summary
Incyte's thesis has shifted from a Jakafi‑centric bet to a race‑against‑time commercial pivot: the stock now depends on multiple recent approvals scaling fast enough (within 12–24 months) and opex being reallocated efficiently to offset a potential >50% Jakafi revenue decline by 2028. Monitor launch KPIs (quarterly US/EU revenue ramps, payer/formulary wins), receivables/inventory and FCF trends—if mid‑2026 shows insufficient traction the current mid‑teens valuation has little cushion.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high gross
- •Strong free cash
- •R&D intensity
INCY delivers high-margin, cash-generative operations with negligible debt but faces risk from heavy R&D intensity and quarterly margin variability. #R&DRisk
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Near-oversold momentum
- •Defined support zone
INCY is in a clear short-term downtrend, down ~10% over the last month to $90.78 with RSI ~26 near oversold, holding support ~$90.8–$92.6 but repeatedly failing to reclaim $100–$102.
~10% drop over the last month with recent sharp daily declines indicating elevated selling pressure
Sentiment & News
Key News Insights:
- •Non‑Jakafi growth
- •Regulatory catalysts
- •Institutional buying
Incyte is shifting its investment thesis toward diversification and imminent regulatory/data catalysts to offset Jakafi patent risk and a below‑peer valuation.
Successful approvals and late‑stage data could drive a valuation re‑rate, but Jakafi's 2028 patent cliff remains a key downside risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings